Evidence map›Paper›PMID 41510817›Full record

ArticleStem cells translational medicine2026

Predicting metabolic dysfunction-associated steatotic liver disease risk using patient-derived induced pluripotent stem cells.

Yuanyuan Qin, Parth Chhetri, Elizabeth Theusch, Grace Lim, Sheila S Teker, Yu-Lin Kuang, Shahrbanoo Keshavarz Aziziraftar, Mohammad Hossein Mehraban, Antonio Munoz-Howell, Varun Saxena and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Stem cells translational medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

14 authors.

Yuanyuan QinDepartment of Pediatrics, University of California San Francisco, Oakland, CA 94609, United States.
Parth ChhetriDepartment of Pediatrics, University of California San Francisco, Oakland, CA 94609, United States.
Elizabeth TheuschDepartment of Pediatrics, University of California San Francisco, Oakland, CA 94609, United States.ORCID 0000-0002-5678-759X
Grace LimDepartment of Pediatrics, University of California San Francisco, Oakland, CA 94609, United States.
Sheila S TekerDepartment of Pediatrics, University of California San Francisco, Oakland, CA 94609, United States.
Yu-Lin KuangDepartment of Pediatrics, University of California San Francisco, Oakland, CA 94609, United States.
Shahrbanoo Keshavarz AziziraftarDepartment of Pathology, University of California San Francisco, San Francisco, CA 94143, United States.
Mohammad Hossein MehrabanDepartment of Pathology, University of California San Francisco, San Francisco, CA 94143, United States.
Antonio Munoz-HowellDepartment of Pediatrics, University of California San Francisco, Oakland, CA 94609, United States.
Varun SaxenaKaiser Permanente South San Francisco, South San Francisco, CA 94080, United States.
Dounia Le GuillouDepartment of Medicine, University of California San Francisco, San Francisco, CA 94143, United States.
Aras N MattisDepartment of Pathology, University of California San Francisco, San Francisco, CA 94143, United States.
Jacquelyn J MaherDepartment of Medicine, University of California San Francisco, San Francisco, CA 94143, United States.
Marisa W MedinaDepartment of Pediatrics, University of California San Francisco, Oakland, CA 94609, United States.ORCID 0000-0002-3631-0129

Funding

UCSF Liver Core CenterP30DK026743 · NIDDK · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Holger Willenbring · 1986 to 2026
$30.7M
Genetic Regulation of Nonalcoholic Fatty Liver DiseaseR01DK130391 · NIDDK · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI MATTIS, ARAS NIKODEMAS, MEDINA, MARISA WONG · 2021 to 2024
$2.2M
California Institute for Regenerative Medicine DISC2-12358NIDDK NIH HHS P30 DK026743NIDDK NIH HHS R01 DK130391NIH HHS R01 DK130391
6 · The paper itself

Abstract

Metabolic dysfunction-associated steatotic liver disease (MASLD) is reversible at early stages, making early identification critical. We previously demonstrated that patient-derived induced pluripotent stem cells (iPSCs) carrying MASLD-associated genetic risk variants exhibit greater oleate-induced intracellular lipid accumulation than those without these variants. This study aimed to develop an iPSC-based MASLD risk predictor using functional lipid accumulation assessments. We quantified oleate-induced lipid accumulation in iPSCs from three cohorts: (1) CIRM (22 cases, 20 controls), (2) POST (18 cases, 16 controls), and (3) UCSF (4 cases, 8 controls). Data from the CIRM cohort was used to define an iPSC-based MASLD risk score, which was subsequently validated in the POST and UCSF cohorts. Lipid accumulation was consistently higher in MASLD iPSCs across cohorts. The risk score achieved 44% sensitivity/75% specificity in POST and 75%/100% in UCSF. These findings suggest that oleate-induced lipid accumulation in iPSCs may be a predictor of MASLD risk. Larger studies incorporating additional cellular phenotypes, clinical, and genetic data could enhance predictive accuracy for MASLD surveillance and prevention.

Indexed as

Fatty LiverInduced Pluripotent Stem CellsAdultFemaleHumansLipid MetabolismMaleMiddle AgedRisk FactorsiPSClipid accumulationMASLDMASLD preventionMASLD risk predictionpatient-derived iPSCs

Identifiers

PMID41510817
PMCPMC12784195

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.